111 related articles for article (PubMed ID: 1651982)
21. Development and in vitro characterization of recombinant vaccinia viruses expressing bovine leukemia virus gp51 in combination with bovine IL4 or IL12.
Von Beust BR; Brown WC; Estes DM; Zarlenga DS; McElwain TF; Palmer GH
Vaccine; 1999 Jan; 17(4):384-95. PubMed ID: 9987178
[TBL] [Abstract][Full Text] [Related]
22. The bovine leukemia virus (BLV) envelope glycoprotein gp51 as a general model for the design of a subunit vaccine against retroviral infection: mapping of functional sites through immunological and structural data.
Callebaut I; Mornon JP; Burny A; Portetelle D
Leukemia; 1994 Apr; 8 Suppl 1():S218-21. PubMed ID: 7512181
[TBL] [Abstract][Full Text] [Related]
23. Humoral immune response of experimentally infected sheep defines two early periods of bovine leukemia virus replication.
Radke K; Grossman D; Kidd LC
Microb Pathog; 1990 Sep; 9(3):159-71. PubMed ID: 1964997
[TBL] [Abstract][Full Text] [Related]
24. Development of a specific serological test and an efficient subunit vaccine to control bovine leukemia virus infection.
Portetelle D; Burny A; Desmettre P; Mammerickx M; Paoletti E; Zavada J
Dev Biol Stand; 1990; 72():81-90. PubMed ID: 1704325
[TBL] [Abstract][Full Text] [Related]
25. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.
Ibuki K; Funahashi SI; Yamamoto H; Nakamura M; Igarashi T; Miura T; Ido E; Hayami M; Shida H
J Gen Virol; 1997 Jan; 78 ( Pt 1)():147-52. PubMed ID: 9010298
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulative effects of bovine immunodeficiency-like virus (BIV)-infection and mixed infection of BIV and bovine leukemia virus on sheep.
Hirai N; Kabeya H; Ohashi K; Sugimoto C; Onuma M
Jpn J Vet Res; 1996 Dec; 44(3):153-63. PubMed ID: 8997876
[TBL] [Abstract][Full Text] [Related]
27. Expression of bovine leukaemia virus envelope gene by recombinant vaccinia viruses.
Kumar S; Andrew ME; Boyle DB; Brandon RB; Lavin MF; Daniel RC
Virus Res; 1990 Oct; 17(2):131-42. PubMed ID: 1963249
[TBL] [Abstract][Full Text] [Related]
28. Identification of an immunodominant region on the isolated bovine leukaemia virus (BLV) major envelope protein gp51 by monoclonal antibodies presumably not exposed during natural BLV infection.
Platzer C; Siakkou H; Sober J; Kopp J; Scheve E; Rosenthal S
Acta Virol; 1990 May; 34(3):246-55. PubMed ID: 1980398
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of tumor necrosis factor alpha mRNA is associated with bovine-leukemia virus (BLV) elimination in the early phase of infection.
Kabeya H; Ohashi K; Oyunbileg N; Nagaoka Y; Aida Y; Sugimoto C; Yokomizo Y; Onuma M
Vet Immunol Immunopathol; 1999 May; 68(2-4):255-65. PubMed ID: 10438324
[TBL] [Abstract][Full Text] [Related]
30. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
31. Long-term protection against bovine leukaemia virus replication in cattle and sheep.
Kerkhofs P; Gatot JS; Knapen K; Mammerickx M; Burny A; Portetelle D; Willems L; Kettmann R
J Gen Virol; 2000 Apr; 81(Pt 4):957-63. PubMed ID: 10725421
[TBL] [Abstract][Full Text] [Related]
32. The influence of ovine MHC class II DRB1 alleles on immune response in bovine leukemia virus infection.
Konnai S; Takeshima SN; Tajima S; Yin SA; Okada K; Onuma M; Aida Y
Microbiol Immunol; 2003; 47(3):223-32. PubMed ID: 12725293
[TBL] [Abstract][Full Text] [Related]
33. Vaccinia virus-expressed bovine ephemeral fever virus G but not G(NS) glycoprotein induces neutralizing antibodies and protects against experimental infection.
Hertig C; Pye AD; Hyatt AD; Davis SS; McWilliam SM; Heine HG; Walker PJ; Boyle DB
J Gen Virol; 1996 Apr; 77 ( Pt 4)():631-40. PubMed ID: 8627251
[TBL] [Abstract][Full Text] [Related]
34. Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine.
Mateo L; Gardner J; Suhrbier A
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1447-53. PubMed ID: 11679157
[TBL] [Abstract][Full Text] [Related]
35. Experimental inoculation of European red foxes with recombinant vaccinia virus expressing zona pellucida C proteins.
Reubel GH; Beaton S; Venables D; Pekin J; Wright J; French N; Hardy CM
Vaccine; 2005 Aug; 23(35):4417-26. PubMed ID: 15936853
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep.
Usui T; Konnai S; Tajima S; Watarai S; Aida Y; Ohashi K; Onuma M
J Vet Med Sci; 2003 Nov; 65(11):1201-5. PubMed ID: 14665749
[TBL] [Abstract][Full Text] [Related]
37. Infection of rats with bovine leukaemia virus: establishment of a virus-producing rat cell line.
Altanerova V; Portetelle D; Kettmann R; Altaner C
J Gen Virol; 1989 Jul; 70 ( Pt 7)():1929-32. PubMed ID: 2544673
[TBL] [Abstract][Full Text] [Related]
38. Immunocompetence of sheep experimentally infected with bovine leukemia virus.
Cockerell GL; Parodi AL; Levy D
Vet Immunol Immunopathol; 1986 Nov; 13(3):189-202. PubMed ID: 3026080
[TBL] [Abstract][Full Text] [Related]
39. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions.
Taylor G; Thomas LH; Furze JM; Cook RS; Wyld SG; Lerch R; Hardy R; Wertz GW
J Gen Virol; 1997 Dec; 78 ( Pt 12)():3195-206. PubMed ID: 9400970
[TBL] [Abstract][Full Text] [Related]
40. Suppression of immunological responses in rabbits experimentally infected with bovine leukemia virus.
Onuma M; Wada M; Yasutomi Y; Yamamoto M; Okada HM; Kawakami Y
Vet Microbiol; 1990 Nov; 25(2-3):131-41. PubMed ID: 2177933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
